HOSPIRA EPHEDRINE SULFATE INJECTION ephedrine sulfate 30mg/1mL Injection ampoule

Country: Ástralía

Tungumál: enska

Heimild: Department of Health (Therapeutic Goods Administration)

Virkt innihaldsefni:

ephedrine sulfate

Fáanlegur frá:

Pfizer Australia Pty Ltd

INN (Alþjóðlegt nafn):

Ephedrine sulfate

Leyfisstaða:

Registered

Upplýsingar fylgiseðill

HOSPIRA™ EPHEDRINE SULFATE
INJECTION
_ _
Ephedrine Sulfate_ (e-FED-rin SUL-fate)_
_ _
CONSUMER MEDICINE INFORMATION
_DATE OF DISPENSING_
_CONSUMER NAME _
_PHARMACIST NAME _
_CONSUMER ADDRESS _
_PHARMACIST ADDRESS _
WHAT IS IN THIS LEAFLET
This leaflet answers some
common questions about
HOSPIRA™ Ephedrine Sulfate
Injection. It does not contain all
the available information.
It does not take the place of
talking to your doctor and
pharmacist.
All medicines have risks and
benefits. Your doctor has
weighed the risks of you being
given HOSPIRA™
Ephedrine
Sulfate Injection against the
benefits this medicine is
expected to have for you.
IF YOU HAVE ANY CONCERNS
ABOUT BEING GIVEN THIS
MEDICINE, ASK YOUR DOCTOR OR
PHARMACIST.
KEEP THIS LEAFLET IN A SAFE
PLACE. You may need to read it
again.
WHAT HOSPIRA™
EPHEDRINE SULFATE
INJECTION IS USED FOR
HOSPIRA™
Ephedrine Sulfate
Injection is used to treat
bronchial asthma, reversible
spasm of the airways, and some
forms of shock. It is also used to
treat the low blood pressure
which may occur during spinal
anaesthesia.
It works by relaxing some of the
muscles in your airways,
stimulating your heart, and
contracting the blood vessels in
your limbs, so that more blood is
available for your brain, heart
and lungs.
_ _
Your doctor may have
prescribed this medicine for
another reason. Ask your doctor
if you have any questions about
why it has been prescribed for
you.
HOSPIRA™ Ephedrine Sulfate
Injection is available only with a
doctor’s prescription.
BEFORE YOU ARE GIVEN
HOSPIRA™
EPHEDRINE SULFATE
INJECTION
_ _
_WHEN YOU MUST NOT BE _
_GIVEN IT _
YOU SHOULD NOT BE GIVEN
HOSPIRA™
EPHEDRINE SULFATE
INJECTION IF:
•
YOU HAVE AN ALLERGY TO
EPHEDRINE OR ANY OF THE
INGREDIENTS LISTED AT THE
END OF THIS LEAFLET
Symptoms of an allergic
reaction to ephedrine may
include:
•
Shortness of breath,
wheezing or difficulty in
breathing
•
swelling of the face, lips,
tongue or other parts of
the body
•
rash, itching or hives on
the skin.
•
YOU HAVE BEEN GIVEN ANY OF
THE FOLLO

Vara einkenni

Product Information - Australia
Version 1.0
Page
1
HOSPIRA™ EPHEDRINE SULFATE INJECTION
NAME OF THE MEDICINE
Ephedrine sulfate
.H
2
SO
4
CH
3
NHMe
H
OH
H
2
The molecular formula of Ephedrine Sulfate is (C
10
H
15
NO)
2
H
2
SO
4
. Its molecular weight is
428.5. The CAS registry number of Ephedrine Sulfate is 134-72-5.
DESCRIPTION
Hospira™ Ephedrine Sulfate Injection is a sterile solution of
Ephedrine Sulfate in Water for
Injections. Each mL contains 30 mg of Ephedrine Sulfate and 3 mg of
Sodium Chloride in
Water for Injections.
PHARMACOLOGY
Ephedrine is a sympathomimetic which stimulates both alpha and beta
adrenergic receptors,
and also releases noradrenaline from storage site. The main effects of
therapeutic doses of
ephedrine are relaxation of bronchial smooth muscle, cardiac
stimulation and increased
systolic and usually diastolic blood pressure via an increase in
cardiac output and peripheral
vasoconstriction. Ephedrine also decreases intestinal tone and
motility, relaxes the bladder
wall, contracts the sphincter muscle, relaxes the detrusor muscle, and
decreases uterine
activity. Ephedrine also has central nervous system stimulant effects.
Tachyphylaxis to the
effects of ephedrine may also occur after use for a short while
possibly due to the depletion
of noradrenaline stores.
PHARMACOKINETICS
Ephedrine is rapidly absorbed after intramuscular or subcutaneous
administration. The onset
of action after intramuscular administration is 10 to 20 minutes, and
the duration of pressor
and cardiac responses to ephedrine is 1 hour after intravenous
administration of 10 to 25 mg
or intramuscular or subcutaneous administration of 25 to 50 mg. Small
quantities of
ephedrine are metabolised in the liver, but the majority of ephedrine
is excreted unchanged in
the urine. The plasma half life of ephedrine is 3 to 6 hours.
Elimination of ephedrine is
increased (and hence the half life is decreased) with decreasing pH of
the urine. Ephedrine is
presumed to cross the placenta, and to be excreted into breast milk.
INDICATIONS